Sihuan Pharma prices second largest healthcare IPO this year

The Chinese manufacturer of cardio-cerebral vascular drugs raises $741 million by pricing its shares at 26.7 times next year's earnings, making it the most expensive new stock to list in Hong Kong this year.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition